Tianjin Medical University Cancer Institute and Hospital
A Randomized Prospective Clinical Trial of Paclitaxel in Combination with Carboplatin Versus Paclitaxel plus Epirubicin as First-Line Treatment in Metastatic Breast Cancer. The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
female ≥ 18 years old, ECOG 0-2 or KPS≥60, Expected lifetime more than 12 weeks.
You may not be if
Pregnancy, Paclitaxel, platinum and anthracycline-based drugs' allergy, Severe Infection.
Clareo Health | Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
